Clinical Trials
Enrolling Trials
        
            1-10  of  118
        
    
Advarra IRB, Cancer Moonshot Biobank Research Protocol
                    Onitilo, Adedayo A
                        Miscellaneous Neoplasm
                            Adult
                            To support current and future investigations into drug resistance and sensitivity and other NCI-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment
                    Marshfield Medical Center - Rice Lake
                                        1700 W STOUT ST
                                        RICE LAKE, WI 54868
                                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    DTL-CIRB-OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
                    Husak, Michael
                        Breast
                            Adult
                            The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
                    Marshfield Medical Center - Rice Lake
                                        1700 W STOUT ST
                                        RICE LAKE, WI 54868
                                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    CIRB, A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
                    Fagbemi, Seth O
                        Gastro-Intestinal (GI)
                            Adult
                            This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
                    Marshfield Medical Center - Rice Lake
                                        1700 W STOUT ST
                                        RICE LAKE, WI 54868
                                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    CIRB-Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
                    Husak, Michael
                        Gastro-Intestinal (GI)
                            Adult
                            This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
                    Marshfield Medical Center - Rice Lake
                                        1700 W STOUT ST
                                        RICE LAKE, WI 54868
                                    MC - Chippewa Falls Center
                                        2655 CTY HWY I
                                        CHIPPEWA FALLS, WI 54729
                                    MC - Wausau Center
                                        2727 PLAZA DRIVE
                                        WAUSAU, WI 54401
                                    MC - Wisconsin Rapids Center
                                        220 24TH ST SOUTH
                                        WISCONSIN RAPIDS, WI 54494
                                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Ladysmith
                                        906 College Ave W 
                                        Ladysmith, WI 54848
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Neillsville
                                        216 Sunset Place
                                        Neillsville, Wisconsin 54456
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    CIRB-Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
                    Edmund, Joseph
                        Gastro-Intestinal (GI)
                            Adult
                            This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.
                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Rice Lake
                                        1700 W Stout St
                                        Rice Lake, WI 54868
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    CIRB, A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
                    Delmastro, Dean A
                        Genitourinary
                                    Urology
                            Adult
                            A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Ladysmith
                                        906 College Ave W 
                                        Ladysmith, WI 54848
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Rice Lake
                                        1700 W Stout St
                                        Rice Lake, WI 54868
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    DTL - CIRB, A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
                    Husak, Michael
                        Genitourinary
                                    Urology
                            Adult
                            This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
                    Marshfield Medical Center - Rice Lake
                                        1700 W STOUT ST
                                        RICE LAKE, WI 54868
                                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    DTL - CIRB, Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
                    Abdelhadi, Kareem H
                        Lymphoma
                            Adult
                            This phase I trial evaluates the side effects and best dose of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Methotrexate is frequently combined with other chemotherapy agents to improve response. This study may help increase the understanding of lenalidomide and nivolumab use in primary CNS lymphoma treatment. In addition, it may help researchers see whether the control of CNS lymphoma can be extended by using these study drugs as maintenance (prolonged therapy) after control is achieved with the initial chemotherapy regimen (induction).
                    Marshfield Medical Center - Rice Lake
                                        1700 W STOUT ST
                                        RICE LAKE, WI 54868
                                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    DTL - CIRB - A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma
                    Fagbemi, Seth O
                        Lymphoma
                            Adult
                            This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Rice Lake
                                        1700 W Stout St
                                        Rice Lake, WI 54868
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                    CIRB, Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
                    Lawler, Benjamin E
                        Central Nervous System
                            Adult
                            This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
                    Marshfield Medical Center - Rice Lake
                                        1700 W STOUT ST
                                        RICE LAKE, WI 54868
                                    MC - Chippewa Falls Center
                                        2655 CTY HWY I
                                        CHIPPEWA FALLS, WI 54729
                                    MC - Wausau Center
                                        2727 PLAZA DRIVE
                                        WAUSAU, WI 54401
                                    MMC - Eau Claire Cancer Center
                                        2200 Craig Road
                                        Eau Claire, WI 54701
                                    MMC - Marshfield
                                        1000 N OAK AVE
                                        MARSHFIELD, WI 54449
                                    MMC - Minocqua
                                        9601 TOWNLINE RD
                                        MINOCQUA, WI 54548
                                    MMC - Stevens Point Campus
                                        4100 WI-66
                                        Stevens Point, WI 54482
                                    MMC - Weston
                                        3501 CRANBERRY BLVD
                                        WESTON, WI 54476
                                     
 